Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Medicine and Dentistry

• Vorinostat 100%
• Cutaneous T Cell Lymphoma 100%
• Mogamulizumab 100%
• Progression Free Survival 27%
• Mycosis fungoides 27%
• Adverse Event 18%
• Sepsis 18%
• Pulmonary Embolism 18%
• Intention-to-Treat Analysis 18%
• Cellulitis 18%
• Diseases 18%
• Oncology 9%
• Non-Hodgkin Lymphoma 9%
• Morbidity 9%
• Randomized Controlled Trial 9%
• Hazard Ratio 9%
• Kidney Function 9%
• Chemokine Receptor 9%
• Systemic Therapy 9%
• Polymyositis 9%
• Liver Function 9%
• Monoclonal Antibody 9%
• Gamma Chemokine 9%
• Effective Treatment 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Vorinostat 100%
• Cutaneous T Cell Lymphoma 100%
• Mogamulizumab 100%
• Syndrome 27%
• Progression Free Survival 27%
• Mycosis fungoides 27%
• Adverse Event 18%
• Cellulitis 18%
• Lung Embolism 18%
• Sepsis 18%
• Diseases 18%
• Randomized Controlled Trial 9%
• Nonhodgkin Lymphoma 9%
• Morbidity 9%
• Chemokine Receptor 9%
• Monoclonal Antibody 9%
• Polymyositis 9%
• Gamma Chemokine 9%
• Bronchopneumonia 9%